Medi-Mibi (Technetium (99mtc) Sestamibi)

Medi-Mibi is used in nuclear medicine to evaluate cardiac and parathyroid conditions through perfusion imaging.

• Myocardial perfusion imaging (stress and rest): enables visualization of regional blood flow and identification of perfusion defects.
• Coronary artery disease detection: assists clinicians in locating ischemic myocardial regions for diagnostic assessment.
• Parathyroid imaging: helps locate hyperfunctioning parathyroid glands prior to surgical intervention.

• Technetium-99m sestamibi is a lipophilic cation that diffuses into cells and accumulates in mitochondria proportionally to regional blood flow. After intravenous injection, the radiotracer is taken up by myocardial and parathyroid cells, emitting gamma photons detectable by scintillation cameras. The distribution pattern reflects perfusion, allowing clinicians to identify areas of reduced flow or abnormal glandular activity.

Adverse reactions to Medi-Mibi are generally related to the radiopharmaceutical nature of the product and the injection process.

Common Side Effects

• Injection site pain: mild discomfort at the venipuncture site.
• Nausea: transient feeling of queasiness following administration.
• Headache: mild to moderate headache occurring shortly after injection.
• Flushing or warmth: brief sensation of warmth or skin flushing.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, or hives indicating hypersensitivity.
• Anaphylaxis: severe, potentially life‑threatening systemic reaction requiring immediate medical attention.
• Radiation‑induced skin injury: localized erythema or ulceration at high exposure sites.

When using Medi-Mibi, several precautions should be observed to ensure patient safety and optimal imaging results.

• Patient preparation: ensure adequate hydration before and after injection to facilitate tracer clearance.
• Contraindications: avoid use in individuals with known hypersensitivity to technetium‑99m sestamibi.
• Pregnancy: do not administer unless the diagnostic benefit outweighs potential fetal radiation risk.
• Radiation safety: follow ALARA principles and protect staff and family from unnecessary exposure.
• Monitoring: observe patients during and after injection for any immediate adverse reactions.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Medi-Mibi may interact with other agents that influence myocardial blood flow or cumulative radiation exposure.

Major Interactions (Avoid)

• Concurrent radiopharmaceuticals: avoid administering other radioactive tracers within a short interval to prevent excessive radiation dose.

Moderate Interactions (Monitor Closely)

• Beta‑blockers, calcium channel blockers, nitrates: these cardiovascular drugs can alter myocardial perfusion and affect imaging interpretation.
• Thyroid hormone therapy: may modify tracer distribution in thyroid tissue.
• Iodinated contrast agents: recent use can interfere with subsequent nuclear imaging studies.
• Chemotherapeutic agents: some may impact organ function and tracer kinetics.